Table 1.
Characteristics of the Trials Included in this Meta-Analysis
| Study | TRD stage | Atypical antipsychotics | Dosage of atypical antipsychotics (mg) | Total number of failed antidepressant trials during current episode before AAP augmentation | Number of historical failure | Presence of prospective antidepressant trial | Duration of prospective antidepressant trial, if any (weeks) | Duration of double- blind phase (weeks) |
|---|---|---|---|---|---|---|---|---|
| Garakani et al., 2008 | Non-TRD | quetiapine | 25–100 | 0 | 0 | no | n/a | 8 |
| Lin et al., 2011 | Non-TRD | aripiprazole | 2.5 | 0 | 0 | no | n/a | 4 (a priori 10 weeks) |
| Mahmoud et al., 2007 | TRD 1 | risperidone | 1 until week 4, 1 or 2 since after | 1 | 1 | yes | 4 | 6 |
| Bauer et al., 2009 | TRD 1 | quetiapine fumarate extended-release | 150, 300 | 1 | 1 | no | n/a | 6 |
| El-Khalili et al., 2010 | TRD 1 | quetiapine fumarate extended-release | 150, 300 | 1 | 1 | no | n/a | 6 |
| Thase et al., 2007 (1) | TRD 2 | OFC | OFC (O 6–18, F 50–100) | 2 | 1 | yes | 8 | 8 |
| Thase et al., 2007 (2) | TRD 2 | OFC | OFC (O 6–18, F 50–100) | 2 | 1 | yes | 8 | 8 |
| Kamijima et al., 2013 | TRD 2–4 | aripiprazole | 3, 3–15 | 2–4 | 1–3 | yes | 8 | 6 |
| Berman et al., 2007 | TRD 2–4 | aripiprazole | 2–20 | 2–4 | 1–3 | yes | 8 | 6 |
| Marcus et al., 2008 | TRD 2–4 | aripiprazole | 2–20 | 2–4 | 1–3 | yes | 8 | 6 |
| Berman et al., 2009 | TRD 2–4 | aripiprazole | 2–20 | 2–4 | 1–3 | yes | 8 | 6 |
AAP, atypical antipsychotic agent; non-TRD, non-treatment resistant depression; OFC, olanzapine-fluoxetine combination; SAT, standard antidepressant therapy; TRD, treatment resistant depression; TRD 1, defined by no history of treatment failure to SAT within the current depressive episode; TRD 2, defined by history of two treatment failures to SAT within the current depressive episode; TRD 2–4, defined by history of two to four treatment failures to SAT within the current depressive episode.